Published in Proteomics Weekly, February 26th, 2007
"The potential role of DNA methylation as a biomarker in leukemia is unknown. In addition, the lack of molecular markers precludes minimal residual disease (MRD) estimation for most patients with hematologic malignancies. We analyzed the potential of aberrant DNA promoter methylation as a biomarker for MRD in acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly